Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?
Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?
复制标题
循证小型综述：铟标记自体血小板扫描是否可以预测慢性免疫性血小板减少症患者对脾切除术的反应？
DOI：
--
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
D. Cines
中科院分区：
文献类型：
--
作者：
A. Cuker;D. Cines
临床场景：一位原本健康的 25 岁女性回到您的办公室接受慢性原发性免疫性血小板减少症的治疗。她在 6 个月前被诊断出来，并继续需要每日 15 毫克泼尼松并定期静脉输注免疫球蛋白以维持止血血小板计数。您讨论了二线治疗方案，包括脾切除术。患者询问是否有任何方法可以预测脾切除术反应的可能性。您听说过为此目的使用铟标记的自体血小板扫描，并且想知道证据表明了什么。
Clinical scenario: An otherwise healthy 25-year-old woman returns to your office for management of chronic primary immune thrombocytopenia. She was diagnosed 6 months earlier and continues to require prednisone 15 mg daily and periodic infusions of intravenous immunoglobulin to maintain a hemostatic platelet count. You discuss second-line treatment options, including splenectomy. The patient asks if there are any means by which to predict likelihood of response to splenectomy. You have heard about the use of indium-labeled autologous platelet scanning for this purpose and wonder what the evidence shows.